Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines

Shiro Saito, Rajat Bannerji, Bernd Gansbacher, Felicia M. Rosenthal, Peter Romanenko, Eli Gilboa, William R. Fair, Eli Gilboa

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

This study explored the use of cytokine gene-modified tumor cells as cellular vaccines for the treatment of bladder cancer. The mouse MBT-2 tumor is an excellent model for human bladder cancer. This carcinogen-induced tumor of bladder origin resembles human bladder cancer in its etiology and histology and responds to treatment in a manner similar to that of its human counterpart. In a previous study we have shown that interleukin 2 (IL-2)- secreting, irradiated, MBT-2 cell preparations were capable of curing animals from orthotopically established tumors and engendered protective immunological memory in the cured animals. In this study we have compared the effectiveness of several cytokines and found that while IL-1α, IL-1β, and γ-interferon were only weakly effective in the therapeutic vaccination protocol, granulocyte-macrophage colony-stimulating factor was almost as effective as but not superior to IL-2, as reported previously for another tumor model system. Induction of cytotoxic T-lymphocyte correlated only poorly with the therapeutic benefit of the cytokine gene-modified tumor cell preparations, questioning its prognostic value for the development of improved genetically modified tumor vaccines.

Original languageEnglish
Pages (from-to)3516-3520
Number of pages5
JournalCancer Research
Volume54
Issue number13
StatePublished - Jul 1 1994
Externally publishedYes

Fingerprint

Cancer Vaccines
Urinary Bladder Neoplasms
Immunotherapy
Cytokines
Genes
Neoplasms
Interleukin-1
Interleukin-2
Immunologic Memory
Cytotoxic T-Lymphocytes
Therapeutics
Granulocyte-Macrophage Colony-Stimulating Factor
Carcinogens
Interferons
Histology
Vaccination
Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Saito, S., Bannerji, R., Gansbacher, B., Rosenthal, F. M., Romanenko, P., Gilboa, E., ... Gilboa, E. (1994). Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Research, 54(13), 3516-3520.

Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. / Saito, Shiro; Bannerji, Rajat; Gansbacher, Bernd; Rosenthal, Felicia M.; Romanenko, Peter; Gilboa, Eli; Fair, William R.; Gilboa, Eli.

In: Cancer Research, Vol. 54, No. 13, 01.07.1994, p. 3516-3520.

Research output: Contribution to journalArticle

Saito, S, Bannerji, R, Gansbacher, B, Rosenthal, FM, Romanenko, P, Gilboa, E, Fair, WR & Gilboa, E 1994, 'Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines', Cancer Research, vol. 54, no. 13, pp. 3516-3520.
Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Gilboa E et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Research. 1994 Jul 1;54(13):3516-3520.
Saito, Shiro ; Bannerji, Rajat ; Gansbacher, Bernd ; Rosenthal, Felicia M. ; Romanenko, Peter ; Gilboa, Eli ; Fair, William R. ; Gilboa, Eli. / Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. In: Cancer Research. 1994 ; Vol. 54, No. 13. pp. 3516-3520.
@article{19512296d6474e338178f730c2915814,
title = "Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines",
abstract = "This study explored the use of cytokine gene-modified tumor cells as cellular vaccines for the treatment of bladder cancer. The mouse MBT-2 tumor is an excellent model for human bladder cancer. This carcinogen-induced tumor of bladder origin resembles human bladder cancer in its etiology and histology and responds to treatment in a manner similar to that of its human counterpart. In a previous study we have shown that interleukin 2 (IL-2)- secreting, irradiated, MBT-2 cell preparations were capable of curing animals from orthotopically established tumors and engendered protective immunological memory in the cured animals. In this study we have compared the effectiveness of several cytokines and found that while IL-1α, IL-1β, and γ-interferon were only weakly effective in the therapeutic vaccination protocol, granulocyte-macrophage colony-stimulating factor was almost as effective as but not superior to IL-2, as reported previously for another tumor model system. Induction of cytotoxic T-lymphocyte correlated only poorly with the therapeutic benefit of the cytokine gene-modified tumor cell preparations, questioning its prognostic value for the development of improved genetically modified tumor vaccines.",
author = "Shiro Saito and Rajat Bannerji and Bernd Gansbacher and Rosenthal, {Felicia M.} and Peter Romanenko and Eli Gilboa and Fair, {William R.} and Eli Gilboa",
year = "1994",
month = "7",
day = "1",
language = "English",
volume = "54",
pages = "3516--3520",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines

AU - Saito, Shiro

AU - Bannerji, Rajat

AU - Gansbacher, Bernd

AU - Rosenthal, Felicia M.

AU - Romanenko, Peter

AU - Gilboa, Eli

AU - Fair, William R.

AU - Gilboa, Eli

PY - 1994/7/1

Y1 - 1994/7/1

N2 - This study explored the use of cytokine gene-modified tumor cells as cellular vaccines for the treatment of bladder cancer. The mouse MBT-2 tumor is an excellent model for human bladder cancer. This carcinogen-induced tumor of bladder origin resembles human bladder cancer in its etiology and histology and responds to treatment in a manner similar to that of its human counterpart. In a previous study we have shown that interleukin 2 (IL-2)- secreting, irradiated, MBT-2 cell preparations were capable of curing animals from orthotopically established tumors and engendered protective immunological memory in the cured animals. In this study we have compared the effectiveness of several cytokines and found that while IL-1α, IL-1β, and γ-interferon were only weakly effective in the therapeutic vaccination protocol, granulocyte-macrophage colony-stimulating factor was almost as effective as but not superior to IL-2, as reported previously for another tumor model system. Induction of cytotoxic T-lymphocyte correlated only poorly with the therapeutic benefit of the cytokine gene-modified tumor cell preparations, questioning its prognostic value for the development of improved genetically modified tumor vaccines.

AB - This study explored the use of cytokine gene-modified tumor cells as cellular vaccines for the treatment of bladder cancer. The mouse MBT-2 tumor is an excellent model for human bladder cancer. This carcinogen-induced tumor of bladder origin resembles human bladder cancer in its etiology and histology and responds to treatment in a manner similar to that of its human counterpart. In a previous study we have shown that interleukin 2 (IL-2)- secreting, irradiated, MBT-2 cell preparations were capable of curing animals from orthotopically established tumors and engendered protective immunological memory in the cured animals. In this study we have compared the effectiveness of several cytokines and found that while IL-1α, IL-1β, and γ-interferon were only weakly effective in the therapeutic vaccination protocol, granulocyte-macrophage colony-stimulating factor was almost as effective as but not superior to IL-2, as reported previously for another tumor model system. Induction of cytotoxic T-lymphocyte correlated only poorly with the therapeutic benefit of the cytokine gene-modified tumor cell preparations, questioning its prognostic value for the development of improved genetically modified tumor vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0028342391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028342391&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 3516

EP - 3520

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -